- August 6, 2018
Experimental Drug Keeps Father Of Two From Needing Kidney Transplant
“We’re studying a medicine called bardoxolone methyl. It’s made by a company called Reata,” explained Block. Hinerfeld was the first person with Alport Syndrome to try bardoxolone. Block said, after 12 weeks, Hinerfeld’s kidney function stopped declining and actually improved.
- August 2, 2018
Celtaxsys cystic fibrosis drug reduces key symptom in mid-stage study
Privately held Celtaxsys Inc said on Thursday a mid-stage trial testing its experimental cystic fibrosis treatment was successful in reducing a key symptom of the genetic lung disease, but did not improve lung function.
- August 2, 2018
Celtaxsys’ cystic fibrosis drug reduces lung exacerbations in phase 2 study
Celtaxsys’ oral anti-inflammatory drug for cystic fibrosis, acebilustat, cleared a phase 2 study by demonstrating meaningful improvements in pulmonary exacerbations, or the acute worsening of symptoms such as heavy coughing or shortness of breath, combined with sharp decreases in lung function following irreversible organ damage.
- July 24, 2018
First Human Trial to Evaluate QR-313 for Dystrophic Epidermolysis Bullosa Initiated
While there are currently no approved treatments for the rare skin disease, there are therapies in development, such as ProQR’s RNA therapy, QR-313, which is now being evaluated in its first human clinical trial, dubbed “WINGS.”
- July 23, 2018
This Biotech Stock Rocketed 40% On Kidney Disease Drug Study
Reata Pharmaceuticals (RETA) skyrocketed to a record high Monday after its experimental drug crushed expectations in two groups of chronic kidney disease patients. Reata said its drug known as bardoxolone methyl benefited patients with what’s known as Alport syndrome and autosomal dominant orphan kidney disease.
- July 13, 2018
Arrowhead Takes Flight
Shares of Pasadena’s Arrowhead Pharmaceuticals Inc. take flight.
- July 12, 2018
Alan Rapoport, MD
At the American Headache Society’s 60th Annual Scientific Meeting, Dr. Alan Rapoport summarizes a poster he presented regarding ZOTRIP, Zosano Pharma’s zolmitriptan patch.
- July 9, 2018
New Effort for Lyme Disease Vaccine Draws Early Fire
In March, Valneva SE , a company based in France, announced initial phase-one clinical trial results after testing its proposed vaccine in 180 healthy adults who took the vaccine with no serious side effects. The study also showed that the vaccine stimulated an immune response, says David Lawrence, chief financial officer of the company.